Market Overview

Top Trending Tickers On StockTwits For February 11

Top Trending Tickers On StockTwits For February 11
Related CSIQ
Solar Stocks Move As US Trade Commission Finds Harm To US Producers From Imports Of Solar Panels
Watch These 7 Huge Put Purchases In Thursday Trade

Here's a look at the top tickers trending on

Regeneron: Net profit lower, sees Eylea growth

This morning, Regeneron Pharmaceuticals (NASDAQ: REGN) reported its fourth quarter results. The company announced an EPS of $2.24, beating the consensus estimate of $2.08. Revenue of $610 million beat the consensus estimate of $579.17 million. Net profit for the quarter fell 79 percent year over year to $97 million due to a non-cash tax benefit of $336 million in the fourth quarter 2012, an income tax provision in 2013 and higher operating costs. The company ended the year with $1.08 billion in cash, nearly double last year's $588 million.

We are pleased with our performance in 2013, with strong EYLEA sales growth globally and continued progress in our pipeline, as well as the launch of our new research initiative in the field of genomics through our Regeneron Genetics Center," said Leonard S. Schleifer, M.D., Ph.D., President and Chief Executive Officer of Regeneron. "Looking forward, in 2014 we expect EYLEA to continue to grow through demographic and geographic expansion, as well as potential approvals in new indications, such as diabetic macular edema. We also look forward to additional clinical data from our Phase 3 program for alirocumab for lowering LDL-cholesterol and Phase 2b data for dupilumab for atopic dermatitis (dupilumab is also being developed for asthma.)

Shares were trading higher by three percent in the pre-market session.

First Solar (NASDAQ: FSLR): Strong industry demand

Bloomberg reported that Centrotherm Photovoaltaics, a German solar company, said that it is seeing surging demand for solar products in the U.S. and Japan.

“The high demand for solar cells and modules, particularly from Japan and the USA, has led to full utilization of their production capacities over the past few months,” the company said, with its single-equipment order book reaching about 62 million euros.

Demand for solar energy in Japan has skyrocketed since July 2012 in an effort to diversify energy sources. The country has been adding 9.3 to 11.8 gigawatts in 2013 after adding as much as 6.8 gigawatts in 2013.

First Solar announced that it had entered the Japanese market in November 2013 with a $100 million investment to develop solar power plants. First Solar considers Japan to be an important market for its products.

“At First Solar, we invest in markets where solar power addresses a fundamental need on a sustainable basis. Japan is adopting a progressive approach by incorporating clean, safe, renewable sources of power in its plans to address the gap created by idle nuclear power,” said James Hughes, CEO, First Solar in a press release following the company's $100 million investment in the country. “First Solar has proven solutions to support Japan's vision of energy security and economic growth, and we will continue to invest here as part of our strategy to develop sustainable solar markets.”

Shares were trading higher by 0.85 percent in the pre-market session.

Tesla: $200 a share, here we go

Shares of Tesla Motors (NASDAQ: TSLA) continues to inch higher towards the $200 a share mark on no new news out.

The options market has been very busy yesterday with roughly 40,000 calls purchased, a rise of 55 percent from its average intraday volume. The most active has been the weekly 2/14 200-strike call.

Tesla's strength over the past few trading sessions is based on a large part on momentum.

Shares were trading higher by one percent at $198.44 in the pre-market session.

Sprint: Smaller fourth-quarter loss

This morning, Sprint (NYSE: S) reported its fourth quarter results. The company announced an EPS of -$0.26, beating the consensus estimate of -$0.33. Revenue of $9.14 million beat the consensus estimate of $7.75 million. It's loss for the quarter narrowed to $1.04 billion from $1.32 billion in the same quarter a year ago.

During the quarter, Sprint added 58,000 net subscribers, lower than the Street's expectations for a net addition of 83,500 net additions. In the third quarter, Sprint lost 360,000 subscribers as it shut down its older Nextel network and many subscribers left due to technical problems related to a massive overhaul of Sprint's remaining network.

Sprint's results comes a day after the Wall Street Journal reported that Sprint is rethinking its attempt to buy T-Mobile U.S. after government regulators expressed skepticism that such an acquisition would be approved.

Shares were trading higher by 6.75 percent in the pre-market session.

Canadian Solar: Announcing plans for a public offering

This morning, Canadian Solar (NASDAQ: CSIQ) announced plans for a public offering of 2.6 million common shares as well as an offering of up to $100 million in convertible senior notes due 2019.

Canadian Solar also said that it expects its fourth quarter revenues to rise 75 percent to $510 million to $520 million from $295 million a year ago.

“For the fourth quarter of 2013, Canadian Solar expects solar module shipments to be in the range of approximately 605 MW to 620 MW, which exceeds the Company's original guidance of 480 MW to 500 MW provided on November 13, 2013,” the company said in a press release. “For the fiscal year 2013 solar module shipments are expected to be in the range of 1,878 MW to 1,893 MW. The Company expects its revenue for the fourth quarter of 2013 to be in the range of $510 million to $520 million. The Company expects its gross margin for the fourth quarter of 2013 including the sale of the Mississippi Mills project in Ontario, Canada, to be in the range of 16% to 18%, compared to its original guidance of 13% to 15% which did not factor in the potential sales of projects from its Ontario, Canada pipeline.”

Shares were trading lower by five percent in the pre-market session.

Posted-In: alirocumab canadian solar EYLEA First Solar Leonard Schleifer Nextel Regeneron PharmaceuticalsNews Best of Benzinga


Related Articles (CSIQ + FSLR)

View Comments and Join the Discussion!

Partner Center